// App-Quantinova.ai

LB0004 (2021) : EFFICACY AND SAFETY OF SECUKINUMAB IN ENTHESITIS-RELATED ARTHRITIS AND JUVENILE PSORIATIC ARTHRITIS: PRIMARY RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREATMENT WITHDRAWAL, PHASE 3 STUDY (JUNIPERA)

Researchers

Presenter

  • N. Ruperto

Principal Investigators

  • E. Alexeeva

  • N. Aktay Ayaz

  • I. Calvo

  • O. Kasapcopur

  • V. Chasnyk

  • M. Hufnagel

  • G. Schulert

  • S. Ozen

  • A. Popov

  • A. Ramanan

  • C. Scott

  • B. Szeri

  • E. Zholobova

  • X. Zhu

  • S. Whelan

  • L. Pricop

  • A. Ravelli

  • A. Martini

  • D. J. Lovell

  • H. Brunner

Medical Centers

  • IRCCS Istituto G. Gaslini, Università di Genova Pediatria, Pediatrics, Genova, Italy

  • Hamburger Zentrum fur Kinder-und Jugend rheumatologie, Hamburg, Germany

  • National Scientific and Practical Center of Children’s Health, Pediatrics, Moscow, Russian Federation

  • Istanbul University, Pediatrics, Istanbul, Turkey

  • Hospital Universitario i Politecnico La Fe Valencia,Valencia,Spagna

  • Istanbul University Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey

  • St. Petersburg State Pediatric Medical Academy, Pediatrics, St. Petersburg, Russian Federation

  • University of Freiburg, Pediatrics and Adolescent Medicine, Freiburg, Germany

  • Wojewodzki Specjalistyczny Szpital Dzieciecy im Sw Ludwika, Pediatrics, Krakow, Poland

  • University of Cincinnati, Pediatrics, Ohio, United States of America

  • Hacettepe University Medical Faculty, Pediatrics, Ankara, Turkey

  • Urals State Medical University, Yekaterinburg, Russian Federation

  • University Hospitals Bristol NHS Foundation Trust and Bristol Medical School, University of Bristol, Bristol, UK, Pediatrics, Bristol, United Kingdom

  • University of Cape Town, Paediatric Rheumatology, Cape Town, South Africa

  • İstanbul Health Sciences University, Pediatric rheumatology, İstanbul, Turkey

  • First Moscow State Medical University, Pediatrics, Moscow, Russian Federation

  • Novartis Pharmaceuticals Corporation, US HEOR, East Hanover, United States of America

  • Novartis Ireland Limited, Clinical Development, Dublin, Ireland

  • Novartis Pharmaceutical Corporation, Clinical Development, East Hanover, United States of America

  • Istituto Giannina Gaslini and Università degli Studi di Genova, Clinica Pediatrica e Reumatologia, Genova, Italy

  • IRCCS Istituto G. Gaslini, Università di Genova Pediatria, Pediatrics, Genova, Italy

  • Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Rheumatology, Cincinnati, United States of America

  • University of Cincinnati, Internal Medicine, Cincinnati, United States of America

Locations

  • Italy

  • Germany

  • Russia

  • Turkey

  • Spain

  • Poland

  • United States

  • United Kingdom

  • South Africa

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • Telomerase reverse transcriptase

  • Albumin/creatinine

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • BMS Infotech

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved